Skip to main content
. 2003 Jun 10;88(12):1851–1858. doi: 10.1038/sj.bjc.6600994

Figure 4.

Figure 4

Adverse events that occurred with ⩾15% incidence in either treatment group in the Q3W and Q4W schedules.